AKT2 and neoplasm: SPC-IGFIR-Akt1−/− mice (n = 9) had significantly reduced tumor burden compared to SPC-IGFIR mice (n = 10) after 9 months of IGF-IR overexpression (Figure 2G, Table 1) while SPC-IGFIR-Akt2−/− mice (n = 12) had significantly increased tumor burden compared to SPC-IGFIR mice (n = 12) after 8 months of IGF-IR overexpression (Figure 2H, Table 1).